Physician profile
Meredith Speight
NPI 1679298590
$2,998.94
in general payments reported to CMS, 2019-2025
23 companies · $2,177 in 2025
The $2,177 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $822 · 2025: $2,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,653 · Education: $302 · Consulting Fee: $43.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,653.02 |
| Education | $302.12 |
| Consulting Fee | $43.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $501.75 | 2024-2025 | Airsupra, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $397.78 | 2024-2025 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $393.64 | 2024-2025 | Dupixent |
| Ars Pharmaceuticals Operations, INC. | $297.54 | 2025 | Neffy |
| Genzyme Corporation | $268.01 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $213.45 | 2024-2025 | Takhzyro, Eohilia, Cuvitru |
| Csl Behring | $145.92 | 2024 | Hizentra, Haegarda |
| Lilly USA, LLC | $121.55 | 2025 | Ebglyss |
| Novartis Pharmaceuticals Corporation | $120.14 | 2025 | |
| Sanofi-Aventis U.S. LLC | $87.99 | 2025 | |
| Grifols USA, LLC | $68.39 | 2024-2025 | Xembify |
| Pharming Healthcare, INC. | $64.34 | 2024-2025 | Ruconest |
| Amgen INC. | $56.39 | 2024-2025 | Tezspire |
| Cycle Pharmaceuticals INC | $46.27 | 2025 | Sajazir |
| Adma Biomanufacturing LLC | $43.80 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $31.25 | 2024 | Yupelri |
| Optinose US, INC. | $27.87 | 2025 | |
| Genentech USA, INC. | $27.79 | 2024-2025 | Xolair |
| Biocryst US Sales Co., LLC | $18.22 | 2025 | Orladeyo |
| Octapharma USA, INC. | $17.84 | 2024 | Cutaquig |
| Blueprint Medicines Corporation | $17.74 | 2024 | Ayvakit |
| Kaleo, INC. | $16.49 | 2024 | Auvi-Q |
| Galderma Laboratories, L.P. | $14.78 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Speight listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.